Initial presentation of early rheumatoid arthritis.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2023
Historique:
received: 23 11 2022
accepted: 09 06 2023
medline: 10 7 2023
pubmed: 6 7 2023
entrez: 6 7 2023
Statut: epublish

Résumé

To study the joint distribution and clinical picture of rheumatoid arthritis (RA) at the initial presentation in seropositive (anti-citrullinated protein antibody (ACPA) and/or rheumatoid factor (RF) positive) and negative patients and the effect of duration of symptoms on the clinical picture. Data of patients who received reimbursement for DMARDs for newly diagnosed RA in 1/2019 to 9/2021 were extracted from the national databases. Joint counts, presence of symmetrical swelling, other disease activity measures, and patient reported outcomes (PROs) were compared in seropositive and negative patients. Regression analyses were applied to compare clinical variables in patients with duration of symptoms of <3, 3-6, and >6 months, adjusted for age, sex, and seropositivity. Data of 1816 ACPA and RF-tested patients were included. Symmetrical swelling was present in 75% of patients. Seronegative versus positive patients had higher value for all disease activity measures and PROs including median swollen joint count (SJC46 10 versus 5) and DAS28 (4.7 versus 3.7), (p<0.001). Patients diagnosed in <3 months had higher median pain VAS (62 versus 52 and 50, p<0.001) and HAQ (1.1 versus 0.9 and 0.75, p = 0.002) compared to those with a duration of symptoms of 3-6 and >6 months. Patients diagnosed >6 months were ACPA-positive more frequently (77% versus 70% in other groups, p = 0.045). Incident RA presents mainly as symmetric arthritis. Seronegative patients have higher disease burden at the initial presentation. Patients experiencing more severe pain and decreased functional ability are diagnosed earlier, regardless of ACPA- status.

Identifiants

pubmed: 37410796
doi: 10.1371/journal.pone.0287707
pii: PONE-D-22-32344
pmc: PMC10325069
doi:

Substances chimiques

Antirheumatic Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0287707

Informations de copyright

Copyright: © 2023 Weman et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Int J Mol Sci. 2014 Dec 03;15(12):22279-95
pubmed: 25479074
Clin Exp Rheumatol. 2003 Sep-Oct;21(5 Suppl 31):S154-7
pubmed: 14969068
Eur J Epidemiol. 2018 Apr;33(4):415-423
pubmed: 29387991
Ann Rheum Dis. 2017 Feb;76(2):341-345
pubmed: 27094444
Arthritis Rheum. 2004 Mar;50(3):953-60
pubmed: 15022339
J Rheumatol. 2014 Dec;41(12):2361-9
pubmed: 25274884
Clin Exp Rheumatol. 2016 Jul-Aug;34(4):641-5
pubmed: 27156863
Ann Rheum Dis. 2013 Jun;72(6):858-62
pubmed: 22798566
Ann Rheum Dis. 2010 Apr;69(4):631-7
pubmed: 20215140
Br Med J. 1978 Nov 25;2(6150):1501
pubmed: 719507
Int J Environ Res Public Health. 2021 Mar 31;18(7):
pubmed: 33807259
J Eval Clin Pract. 2008 Dec;14(6):1044-9
pubmed: 19019098
Curr Opin Rheumatol. 2010 Mar;22(2):109-18
pubmed: 20075733
Reumatologia. 2017;55(4):169-176
pubmed: 29056771
Ann Rheum Dis. 2015 Mar;74(3):e12
pubmed: 24534758
Rheumatology (Oxford). 2021 May 14;60(5):2391-2395
pubmed: 33175968
Arthritis Rheum. 2010 Dec;62(12):3537-46
pubmed: 20722031
Ann Rheum Dis. 2017 Jun;76(6):e14
pubmed: 27932346
Rheumatology (Oxford). 2002 Mar;41(3):246-52
pubmed: 11934959
Arthritis Res Ther. 2019 Jun 6;21(1):140
pubmed: 31171038
Ann Rheum Dis. 1995 Dec;54(12):944-7
pubmed: 8546524
Clin Exp Rheumatol. 2019 Jan-Feb;37(1):37-43
pubmed: 29998832
Arthritis Res Ther. 2009;11(1):R7
pubmed: 19144159
Ann Rheum Dis. 2017 Feb;76(2):315-317
pubmed: 27658679
Arthritis Rheum. 1995 Jan;38(1):44-8
pubmed: 7818570
Joint Bone Spine. 2005 May;72(3):241-7
pubmed: 15850996
Arthritis Rheum. 2010 Sep;62(9):2569-81
pubmed: 20872595

Auteurs

Lauri Weman (L)

University of Eastern Finland and Jyväskylä Central Hospital, Jyväskylä, Finland.

Henri Salo (H)

Finnish Institute for Health and Welfare (THL), Data and Analytics, Helsinki, Finland.

Laura Kuusalo (L)

Department of Internal Medicine, University of Turku and Turku University Hospital, Turku, Finland.

Johanna Huhtakangas (J)

Division of Rheumatology, Kuopio University Hospital, Kuopio, Finland.

Johanna Kärki (J)

Department of Children and Adolescents, Kanta-Häme Central Hospital, Hämeenlinna, Finland.

Paula Vähäsalo (P)

Department of Children and Adolescents, Research Unit of Clinical Medicine, University of Oulu, Oulu University Hospital and Medical Research Center, Oulu University Hospital and University of Oulu, Oulu, Finland.

Maria Backström (M)

Department of Paediatrics, Wellbeing Services County of Ostrobothnia, Vaasa, Finland.
Research Unit of Clinical Medicine, University of Oulu, Oulu, Finland.

Tuulikki Sokka-Isler (T)

University of Eastern Finland and Jyväskylä Central Hospital, Jyväskylä, Finland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH